Nabhani Zohoor, Clark Cain C T, Goudarzi Nazanin, Hariri Far Alemeh, Razmpoosh Elham
Nutrition Research Center, Department of Biochemistry and Diet Therapy, Faculty of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Centre for Intelligent Healthcare, Coventry University, Coventry, CV1 5FB, UK.
Diabetol Metab Syndr. 2022 Jun 21;14(1):87. doi: 10.1186/s13098-022-00858-1.
Women with GDM have a higher risk of future cardiovascular diseases (CVD). Meanwhile, synbiotics have been demonstrated to have favorable impacts on atherogenic indices, and inflammatory and oxidative stress indicators, all of which are known to be CVD-predictive factors. The aim of this randomized controlled trial was to evaluate the effects of synbiotic supplementation on the atherogenic indices of plasma, high-sensitivity C-reactive protein (hs-CRP), and plasma malondialdehyde (MDA) in women with GDM.
Eligible pregnant women with GDM were randomized into two groups to receive a daily synbiotic capsule [500 mg of L.acidophilus(5 × 10 CFU/g), L.plantarum(1.5 × 10 CFU/g), L.fermentum(7 × 10 CFU/g), L.Gasseri(2 × 10 CFU/g) and 38.5 mg of fructo-oligo-saccharides], or placebo, for 6 weeks. The ratios of TC/HDL-C, LDL/HDL-C, and logTG/HDL-C were calculated as the atherogenic indices. Serum hs-CRP and MDA concentrations were quantified before and after the intervention. Cohen's d(d) was used to calculate the magnitude of the effect.
Ninety participants completed the study. There was no significant difference in dietary antioxidant and mineral intakes between the two groups. Compared with placebo, synbiotic supplementation resulted in a significant decrease in logTG/HDL-C ratio with a medium-low effect size (mean difference = -0.11; 95% CI -0.21, 0; P values for the placebo and the intervention groups were 0.02, and 0.042, respectively; P between groups = 0.003; d = 0.25). No significant changes were observed in other parameters.
Overall, 6 weeks of synbiotic supplementation in women with GDM resulted in a significant improvement in logTG/HDL-C, suggesting that synbiotics may have a beneficial role in reducing the risk of future CVDs associated with GDM. Nevertheless, more studies are needed to confirm the veracity of these results. Trial Registration IRCT201511183140N16 (December 29th, 2015).
妊娠期糖尿病（GDM）女性未来患心血管疾病（CVD）的风险更高。同时，已证明合生制剂对致动脉粥样硬化指数、炎症和氧化应激指标有积极影响，而这些均为已知的心血管疾病预测因素。本随机对照试验的目的是评估补充合生制剂对GDM女性血浆致动脉粥样硬化指数、高敏C反应蛋白（hs-CRP）和血浆丙二醛（MDA）的影响。
符合条件的GDM孕妇被随机分为两组，一组每天服用一粒合生制剂胶囊[500毫克嗜酸乳杆菌（5×10⁸CFU/g）、植物乳杆菌（1.5×10⁸CFU/g）、发酵乳杆菌（7×10⁸CFU/g）、加氏乳杆菌（2×10⁸CFU/g）和38.5毫克低聚果糖]，另一组服用安慰剂，为期6周。计算总胆固醇/高密度脂蛋白胆固醇（TC/HDL-C）、低密度脂蛋白/高密度脂蛋白胆固醇（LDL/HDL-C）和log甘油三酯/高密度脂蛋白胆固醇（logTG/HDL-C）的比值作为致动脉粥样硬化指数。在干预前后对血清hs-CRP和MDA浓度进行定量。采用科恩d值（d）计算效应大小。
90名参与者完成了研究。两组之间的饮食抗氧化剂和矿物质摄入量没有显著差异。与安慰剂相比，补充合生制剂导致logTG/HDL-C比值显著降低，效应大小为中低水平（平均差异=-0.11；95%置信区间为-0.21, 0；安慰剂组和干预组的P值分别为0.02和0.042；组间P=0.003；d=0.25）。其他参数未观察到显著变化。
总体而言，GDM女性补充6周合生制剂可使logTG/HDL-C显著改善，这表明合生制剂可能在降低与GDM相关的未来心血管疾病风险方面发挥有益作用。然而，需要更多研究来证实这些结果的真实性。试验注册号：IRCT20151118314N16（2015年12月日） 。 29
